Thickening of the lungs refers to the buildup of scar tissue, inflammatory material, or excess connective tissue within the lung’s delicate internal structures, making the tissue stiffer and less able to transfer oxygen into the bloodstream. The medical term most commonly associated with this process is pulmonary fibrosis, though thickening can also affect the lining around the lungs (the pleura) or the walls of the airways themselves. The causes range from inhaled environmental substances to autoimmune diseases, viral infections, certain medications, and genetic predisposition, and in the most common serious form, the cause remains genuinely unknown.
What “Thickening” Actually Means Inside the Lung
Your lungs are not solid organs. They are elaborate networks of tiny air sacs called alveoli, surrounded by extremely thin walls of tissue laced with blood vessels. Oxygen crosses these thin walls to enter your blood, and carbon dioxide crosses back out to be exhaled. When those walls thicken, gas exchange becomes harder. The lung essentially loses its ability to do its primary job efficiently. When lung tissue is injured, the structural complexity of the lung gets disrupted, and that disruption directly impairs gas exchange.1PubMed Central. Pathophysiology of respiratory failure and physiology of gas exchange during ECMO
Thickening can happen in several distinct locations. The interstitium is the scaffolding tissue between and around the air sacs; this is where most fibrotic lung diseases cause their damage. The pleura is the membrane surrounding each lung, and it can thicken independently or alongside deeper lung disease. Any fibrotic lung disease affecting the small airways and pleura can produce areas of pleural thickening or irregularity.2Seminars in Roentgenology. Pleural Thickening: Detection, Characterization, and Differential Diagnosis – Section: Pleuroparenchymal Fibroelastosis and Other Interstitial Lung Diseases And the airway walls themselves can thicken if scarring develops around the bronchial tubes. These are related but not identical problems, and different diseases tend to favor different locations.
How Scarring Develops in the Lung
The underlying process behind most lung thickening is fibrosis, which is essentially the body’s wound-healing system stuck in overdrive. When lung tissue is damaged, whether by infection, a chemical irritant, or radiation, the body sends repair signals to patch things up. In a healthy response, the repair wraps up and the tissue returns roughly to normal. In fibrosis, the repair process never shuts off. Fibrous connective tissue keeps accumulating at the damage sites, and this buildup progressively reduces lung function and can ultimately lead to respiratory failure.3PubMed Central. Full recovery of lung tissue after severe viral pneumonia H1N1: A case report with 10 years follow-up – Section: Discussion
One of the key chemical signals driving this runaway repair is a protein called TGF-beta (transforming growth factor-beta). In normal healing, TGF-beta helps coordinate tissue repair, immune calming, and rebuilding of the tissue scaffold. But when TGF-beta signaling stays switched on too long or too intensely, it pushes cells down a path toward irreversible scarring rather than normal recovery.4PubMed Central. TGF-β Signaling as a Pathological Continuum Linking Idiopathic Pulmonary Fibrosis and Lung Cancer In mouse models, elevated TGF-beta levels lead to measurably thicker tissue deposits around the airways and increased airway stiffness.5PubMed. Lung-specific TGFβ overexpression increases airway fibrosis and airway contractility in transgenic mice Understanding this signaling pathway matters because most current and experimental treatments for lung fibrosis are designed to interrupt it.
Idiopathic Pulmonary Fibrosis
The most well-known and, frustratingly, the least understood form of lung thickening is idiopathic pulmonary fibrosis (IPF). “Idiopathic” simply means the cause has not been identified. IPF is a progressive, fatal interstitial lung disease marked by excessive deposition of collagen and other structural proteins that gradually destroy the lung’s architecture.6PubMed Central. Organelle Crosstalk and Metabolic Reprogramming in Idiopathic Pulmonary Fibrosis: Mechanisms and Therapeutic Implications Despite decades of research, its root cause remains unclear.7PubMed Central. Pulmonary fibrosis: pathogenesis, etiology and regulation
IPF typically affects adults over fifty, and it tends to progress relentlessly. Lung function declines over months to years, and existing antifibrotic drugs can slow the process but do not fully stop it.8PubMed Central. The role of glutamine metabolism in the pathogenesis of idiopathic pulmonary fibrosis and its therapeutic potential What makes IPF particularly challenging is that it can look similar on scans and biopsies to other types of lung fibrosis that do have known causes, which makes ruling out other possibilities a critical part of diagnosis.
There is a genetic dimension. In some families with IPF, researchers have found mutations in the genes responsible for telomerase, the enzyme that maintains the protective caps on the ends of chromosomes. Short telomeres limit the lung’s ability to renew its own tissue, and inherited mutations in telomerase components have been linked to familial IPF.9PubMed Central. Short telomeres are a risk factor for idiopathic pulmonary fibrosis This does not mean IPF is straightforwardly inherited the way some genetic conditions are, but it does mean that some people carry a biological vulnerability that makes their lungs less resilient to the kinds of low-grade damage that most lungs handle without trouble.
Environmental and Occupational Exposures
Many forms of lung thickening have a clear external trigger. Hypersensitivity pneumonitis (HP) is a condition in which the lungs develop inflammation and, over time, fibrosis in response to repeated inhalation of organic dusts or certain chemicals. These can be animal proteins (bird droppings and feathers are classic culprits), molds, bacteria growing in humidifiers or air conditioning systems, or industrial chemicals. HP is driven by an immune overreaction in people who are sensitized to the offending substance.10PubMed Central. Hypersensitivity pneumonitis: a complex lung disease
In acute or short-term exposure, HP may cause flu-like symptoms and lung inflammation that resolves once you stop breathing in the trigger. But chronic, repeated exposure can lead to permanent fibrotic changes. Chronic HP is a recognized interstitial lung disease resulting from long-term immune-driven inflammation and scarring.11Journal of Clinical Images and Medical Case Reports. Familial clustering in chronic hypersensitivity pneumonitis: Diagnostic dilemmas and role of lung biopsy The challenge with chronic HP is that by the time fibrosis is established, removing the antigen source may slow progression but will not reverse the scarring that has already occurred.
Workplace exposures are another well-documented cause. Occupational lung diseases are a broad group of preventable conditions caused by inhaling harmful substances at work, and they can be classified into fibrotic and non-fibrotic forms, with imaging showing variable degrees of inflammation and fibrosis across the airways, lung tissue, and pleura.12PubMed Central. Occupational Lung Diseases: Spectrum of Common Imaging Manifestations Workers exposed to silica dust, asbestos, coal dust, and certain metal particles face elevated risks of developing progressive lung fibrosis. Asbestosis, for example, causes both thickening of the lung tissue itself and characteristic thickening of the pleura. These diseases are considered preventable because they arise from identifiable exposures, yet they continue to occur worldwide, particularly in industries where dust control and respiratory protection are inadequate.
Infections and Post-Viral Scarring
Lung thickening is an increasingly recognized consequence of severe respiratory infections. Pulmonary fibrosis following infection is characterized by excessive deposits of structural proteins and irreversible architectural damage to the lung.13PubMed Central. Scar wars: the viral menace While fibrosis after pneumonia was understood before 2020, the COVID-19 pandemic put a spotlight on the problem. Many survivors of severe viral pneumonia do not recover fully but instead develop chronic fibrotic changes that continue to impair lung function long after the initial infection has cleared.13PubMed Central. Scar wars: the viral menace
The mechanism is essentially the same wound-healing-gone-wrong process described earlier. A severe infection causes extensive damage to the thin walls of the alveoli. The body mounts a repair response. In some people, especially those who experienced acute respiratory distress syndrome (ARDS) during their illness, the repair overshoots and leaves behind stiff, scarred tissue. Not everyone who has a bad bout of pneumonia develops lasting fibrosis, but the risk rises with the severity of the initial lung injury. Influenza, coronaviruses, and other respiratory viruses have all been associated with post-infectious fibrotic changes.
Medications and Radiation
A surprising number of medications can cause interstitial lung disease, including inflammation and fibrosis. Drug-induced interstitial lung disease has been linked to chemotherapy agents, certain antibiotics, heart rhythm drugs, and immunosuppressive medications.14PubMed Central. Drug induced interstitial lung disease One of the best-studied examples is amiodarone, a widely used antiarrhythmic drug whose clinical use is limited by the risk of inducing pulmonary fibrosis.15PubMed Central. Network toxicology reveals key genes of amiodarone induced pulmonary fibrosis: based on machine learning and SHAP analysis Drug-induced lung toxicity can be tricky to diagnose because the symptoms, including cough, breathlessness, and changes on imaging, overlap with those of the disease the medication was originally treating.
Radiation therapy for cancers in and around the chest is another established cause. Lung injury from radiation ranges from acute inflammation (radiation pneumonitis) to chronic pulmonary fibrosis, depending on the dose, the volume of lung exposed, and the individual patient’s susceptibility. Radiation pneumonitis typically shows up weeks to months after treatment, while the fibrotic phase develops over months to years and is generally irreversible. Diagnosing radiation-induced lung injury involves confirming the history of radiation exposure, matching imaging findings to the radiation field, and ruling out other causes such as infection or tumor progression.
Autoimmune Diseases
Systemic autoimmune diseases, where the immune system attacks the body’s own tissues, frequently involve the lungs. In fact, in conditions such as rheumatoid arthritis, scleroderma, lupus, and various forms of vasculitis, any compartment of the pulmonary system can be independently or simultaneously affected by immune-driven inflammation and scarring.16PubMed Central. Pulmonary manifestations of systemic autoimmune diseases In some patients, lung involvement is actually the first sign of an underlying autoimmune condition, appearing before joint pain, skin changes, or other more recognizable symptoms.
The pattern of lung thickening in autoimmune disease varies. Scleroderma, for instance, tends to cause a pattern called nonspecific interstitial pneumonia, while rheumatoid arthritis can produce a pattern that looks very similar to IPF on imaging. This overlap creates diagnostic challenges: a patient with lung fibrosis needs to be evaluated for underlying autoimmune disease, because identifying and treating the systemic condition can sometimes slow or stabilize the lung damage in ways that are not possible when fibrosis is truly idiopathic.
How Lung Thickening Is Found and Measured
High-resolution CT scanning (HRCT) is the most important imaging tool for evaluating lung thickening. It has contributed enormously to the diagnosis and classification of interstitial lung diseases and is particularly useful in identifying patterns associated with different types of fibrosis.17PubMed Central. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias On HRCT, doctors look for specific patterns: honeycombing (a pattern of small cystic spaces that signals advanced fibrosis), ground-glass opacities (hazy areas that may indicate early fibrotic or inflammatory changes), and thickened walls between the lung’s compartments.18PubMed. Quantitative Micro-CT Analysis of Lung Parenchymal and Airway Remodeling in a Ferret Model of Pulmonary Fibrosis
Ultrasound can be useful for evaluating pleural thickening and fluid around the lungs with very high accuracy, but it performs less well for detecting disease deeper within the lung tissue itself.19The Journal of Community Health Management. Role of ultrasound in diagnosis of pleural and parenchymal lung diseases in OPD patients Lung function tests, particularly measurements of how much air you can blow out (spirometry) and how well oxygen crosses from your lungs into your blood (diffusion capacity), give doctors a functional picture of how much the thickening is actually affecting your breathing.
Blood biomarkers are an active area of research. Several proteins measured in blood samples show promise for helping to distinguish IPF from other types of interstitial lung disease, to predict how quickly the disease is progressing, and to monitor disease severity over time.20PubMed Central. Peripheral blood biomarkers in idiopathic pulmonary fibrosis One of the more studied markers is KL-6, a protein whose blood levels are elevated in several fibrosing lung diseases. Surfactant proteins SP-A and SP-D, which are normally produced by cells lining the air sacs, also show elevated blood levels in various fibrosing conditions, and higher levels have been associated with progressive disease and declining lung function.21CHEST. Biomarkers in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype – Section: Diagnostic Biomarkers None of these biomarkers are yet reliable enough to replace CT scans or biopsies, but they are increasingly used alongside imaging to build a fuller picture.
Treatment Approaches
Treatment for lung thickening depends entirely on the underlying cause. When the trigger is identifiable, such as an environmental exposure or a medication, removing that trigger is the first and most important step. For autoimmune-related lung disease, treating the systemic condition with immunosuppressive therapies can sometimes stabilize or slow the fibrotic process. For drug-induced disease, stopping the offending medication may allow some degree of recovery, though established fibrosis tends to be permanent.
For IPF and other progressive fibrosing lung diseases, two antifibrotic drugs, pirfenidone and nintedanib, are currently approved. Both slow the rate of lung function decline rather than reversing existing scarring. Nintedanib works in part by blocking the proliferation of fibroblasts, the cells responsible for producing scar tissue, and by interfering with TGF-beta signaling pathways that drive the fibrotic process.22PubMed Central. Inhalable Albumin Nanoparticles Co-Delivering Dihydroartemisinin and Nintedanib Attenuate Pulmonary Fibrosis by Suppressing TGF-β1/Smad2/3 Signaling Newer agents are being tested in trials. Nerandomilast, for example, has shown in preclinical models that it can reduce levels of inflammatory and fibrotic signaling molecules in the context of rheumatoid arthritis-associated lung disease.23PubMed Central. Nerandomilast (BI 1015550) attenuating pulmonary fibrosis in a mouse model of rheumatoid arthritis-associated interstitial lung disease by modulating the TGF-β1/PI3K/Akt signaling pathway
Pulmonary rehabilitation, which involves supervised exercise training and breathing techniques, does not reverse fibrosis either, but it makes a meaningful difference in how people function day to day. A Cochrane review of the evidence found that pulmonary rehabilitation improves the distance people with interstitial lung disease can walk in six minutes by roughly 40 meters on average, and it likely improves breathlessness and overall quality of life.24PubMed Central. Pulmonary rehabilitation for interstitial lung disease For people living with progressive lung fibrosis, that kind of improvement in daily functioning matters a great deal even if the underlying disease continues to progress. Supplemental oxygen is prescribed when blood oxygen levels drop, and for advanced disease, lung transplantation remains the only option that can restore lung function.
Lung Thickening in Children
While most discussions of pulmonary fibrosis focus on adults, children can develop interstitial lung disease too. The causes in children are different and often genetic. One recognized pediatric form involves mutations in the gene for surfactant protein C, a substance that helps keep the air sacs inflated and functioning. In affected children, imaging shows progressive interstitial thickening and fibrosis that worsens with age, typically concentrated in the lower portions of both lungs.25Applied Radiology. Surfactant Protein C Deficiency-associated Diffuse Lung Disease – Section: Imaging Findings Pediatric interstitial lung disease is rare and often requires specialized genetic testing and pediatric pulmonology expertise to diagnose, since the usual adult workup may not uncover the underlying problem.
Experimental Therapies and Where Research Is Heading
The limitations of current antifibrotic drugs have pushed researchers toward fundamentally different treatment strategies. Stem cell therapy is one of the most actively investigated. Mesenchymal stem cells, derived from bone marrow, fat tissue, or umbilical cord, have properties that make them attractive candidates: they trigger relatively little immune rejection, they can migrate toward sites of injury, and they release a cocktail of anti-inflammatory and tissue-repair signals. In preclinical studies, these cells and their secreted particles have been shown to block TGF-beta signaling pathways, shift immune cells toward less inflammatory behavior, and promote tissue regeneration.26PubMed Central. Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis The body of preclinical evidence supporting their potential is substantial.27PubMed Central. Stem cell-based therapy for pulmonary fibrosis
The gap between promising animal data and effective human treatment remains wide, though. Stem cell therapies face practical challenges around how to deliver cells to the right part of the lung, how to keep them alive and functional long enough to make a difference, and how to scale up production for clinical use. Early-phase clinical trials are underway, but it will be years before anyone knows whether stem cells can meaningfully alter the course of pulmonary fibrosis in people. In the meantime, research into novel drug delivery methods, including inhalable nanoparticles that deliver antifibrotic medications directly to lung tissue, is also gaining traction as a way to improve on the drugs that already exist.22PubMed Central. Inhalable Albumin Nanoparticles Co-Delivering Dihydroartemisinin and Nintedanib Attenuate Pulmonary Fibrosis by Suppressing TGF-β1/Smad2/3 Signaling The logic is straightforward: delivering medication directly to the lung could reduce side effects and increase the amount of drug reaching the fibrotic tissue, compared to swallowing a pill and waiting for it to circulate through the entire body.
Another area of growing interest is metabolic reprogramming. Researchers have discovered that fibrotic cells in the lung have altered metabolism, relying heavily on certain amino acids to fuel their production of collagen and maintain their activated state. If those metabolic pathways could be selectively disrupted, it might be possible to starve the fibrotic process without harming healthy lung tissue.8PubMed Central. The role of glutamine metabolism in the pathogenesis of idiopathic pulmonary fibrosis and its therapeutic potential This approach is still in its early stages, but it represents a fundamentally different angle from the signaling-pathway inhibitors that dominate current treatment.